Eli Lilly and Company (LLY)
Looking to diversify away from AI trade? Buy these 3 stocks
For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced volatility, shifting capital toward overlooked equities offers a compelling strategic alternative. Market participants are increasingly adopting a “defensive posture” against a possible downturn – pivoting to segments where high-quality operators with solid fundamentals have fallen out of favor leading to unwarranted valuation de-ratings.
Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company.
Eli Lilly's $3.8bn psychedelics bet is built on British science
Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic compound 5-MeO-DMT developed by Beckley Psytech, the Oxford company founded by Amanda Feilding and her son Cosmo Feilding Mellen.
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has agreed to pay $6.75 a share in cash upfront ($2.8 billion) – with an additional $2.5 a share in contingent value rights (CVRs) tied to critical clinical and regulatory milestones.
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio. Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.
This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
Eli Lilly is in talks to buy a psychedelic drugmaker at a premium, according to a report.
It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.
Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher
Eli Lilly (NYSE:LLY | LLY Price Prediction) has whipsawed shareholders in 2026, but the setup heading into the second half looks compelling.
Eli Lilly's $400 Billion Surge Is Reshaping Big Pharma
Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY | LLY Price Prediction) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker's market capitalization to $1.063 trillion.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strong LLY News Boosts Active Healthcare ETF GDOC
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.
